Loading…
Intellia Therapeutics, Inc. is projected to rise to $16.19 by 2027, a +20% move from its current price of $13.44. NTLA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $12.92 | $13.45 | $13.99 | +0.06% |
| May 30 | $12.72 | $13.46 | $14.24 | +0.13% |
| May 31 | $12.57 | $13.47 | $14.43 | +0.19% |
| Jun 1 | $12.44 | $13.47 | $14.59 | +0.25% |
| Jun 2 | $12.33 | $13.48 | $14.74 | +0.31% |
| Jun 3 | $12.24 | $13.49 | $14.87 | +0.38% |
| Jun 4 | $12.15 | $13.50 | $15.00 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.15 | $13.50 | $15.00 | +0.44% |
| Week 2 | $11.68 | $13.56 | $15.74 | +0.88% |
| Week 3 | $11.35 | $13.62 | $16.34 | +1.33% |
| Week 4 | $11.08 | $13.68 | $16.88 | +1.77% |
| Week 5 | $10.86 | $13.74 | $17.39 | +2.22% |
| Week 6 | $10.66 | $13.80 | $17.86 | +2.67% |
| Week 7 | $10.49 | $13.86 | $18.31 | +3.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Intellia Therapeutics, Inc. is a clinical-stage healthcare company that focuses on genome editing using CRISPR/Cas9-based technologies to develop potentially curative therapeutics. It provides a modular platform to advance in vivo and ex vivo therapies for diseases, with in vivo product candidates NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema.
The company was incorporated in 2014, was formerly known as AZRN, Inc., and changed its name to Intellia Therapeutics, Inc. in July 2014. It is headquartered in Cambridge, Massachusetts.
Intellia maintains collaboration and license relationships with several partners to develop genomic medicines and therapies, including AvenCell Therapeutics, Kyverna Therapeutics, ONK Therapeutics, ReCode Therapeutics, Regeneron Pharmaceuticals, SparingVision SAS, and Rewrite Therapeutics Inc. These arrangements support its efforts across immuno-oncology, autoimmune diseases, and other diseases that may benefit from gene editing.
With a broad platform and multiple programs, Intellia aims to advance gene editing therapeutics across organ systems beyond the liver and to bring potential treatments to patients through a clinical-stage development path.
NTLA is the stock of Intellia Therapeutics, Inc., a clinical-stage healthcare company focused on CRISPR/Cas9 genome editing. The current price is $12.60, and the company has a market capitalization of $1.76B, ranking 2093 by market cap. The stock trades in a market context where a multi-year forecast shows bullish momentum developing after 2026, with notable upside in the 2030s and 2040s.
The latest price action sits near the 50-day and 200-day simple moving averages, suggesting a nuanced near-term picture. The forecasted path projects higher averages in the long run, with significant upside potential by 2040 and beyond, though near-term volatility and variability remain under the outlook.
A major floor 30.4% below — a decisive break under it would weaken the trend.
The nearest floor, 11.2% below — buyers have tended to step in here.
The nearest ceiling, 23.3% above — a clean break opens room to run.
A major ceiling 38.5% above — clearing it would confirm fresh momentum.
Key NTLA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NTLA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.66 | Buy | $12.88 | Buy |
| MA 10 | $12.89 | Buy | $12.96 | Buy |
| MA 20 | $13.27 | Buy | $13.22 | Buy |
| MA 50 | $13.55 | Sell | $13.37 | Buy |
| MA 100 | $13.13 | Buy | $13.17 | Buy |
| MA 200 | $13.25 | Buy | $13.03 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.85 | Neutral |
| Stoch RSI (14) | 77.89 | Neutral |
| CCI (20) | 18.55 | Neutral |
| Williams %R (14) | -39.52 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -4.61 | Sell |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 60.48 | Neutral |
| TRIX (15) | -0.25 | Sell |
| Awesome (5,34) | -1.13 | Sell |
| Ultimate (7,14,28) | 46.76 | Neutral |
| Momentum (10) | -0.55 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 12.74 | Buy |
| ADX (14) | 10.35 | Neutral |
| ATR (14) | 0.51 | Info |
The near-term technical picture is neutral. The RSI(14) is 40, indicating neither overbought nor oversold conditions. The 50-day simple moving average sits at $13.56 and the 200-day simple moving average at $13.23, placing the stock around a supportive zone near the mid-$13s.
The stock’s nearest support is $11.94, with resistance at $16.57. Over the last 30 days, the price traded in a range from $9.68 to $16.40, highlighting a broad, unsettled trading band and room for movement depending on news and sector sentiment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.21 | $13.44 | $20.30 | 0% | Neutral | |
| $12.27 | $16.19 | $22.93 | +20% | Bullish | |
| $13.60 | $18.70 | $27.81 | +39% | Bullish | |
| $12.75 | $18.17 | $28.06 | +35% | Bullish | |
| $12.52 | $18.42 | $29.37 | +37% | Bullish | |
| $16.91 | $25.61 | $42.00 | +91% | Bullish | |
| $19.12 | $29.77 | $50.05 | +122% | Bullish | |
| $20.23 | $32.35 | $55.62 | +141% | Bullish | |
| $22.21 | $36.43 | $63.92 | +171% | Bullish | |
| $20.82 | $34.99 | $62.57 | +160% | Bullish | |
| $32.25 | $60.74 | $117.53 | +352% | Bullish | |
| $44.45 | $98.78 | $213.97 | +635% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $9.21 | $13.44 | $15.84 | +0.00% |
| June 2026 | $11.39 | $13.51 | $16.51 | +0.55% |
| July 2026 | $11.85 | $14.23 | $17.72 | +5.31% |
| August 2026 | $11.90 | $14.43 | $18.24 | +1.39% |
| September 2026 | $11.53 | $14.10 | $18.03 | -2.30% |
| October 2026 | $11.78 | $14.50 | $18.75 | +2.89% |
| November 2026 | $12.35 | $15.31 | $19.98 | +5.54% |
| December 2026 | $12.36 | $15.42 | $20.30 | +0.73% |
Click any year to see its month-by-month NTLA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The NTLA price prediction for 2026 points to an average of $13.44 (low $9.21, high $20.30) — a potential gain of 0% on today's $13.44. Price action looks broadly range-bound.
In 2027, NTLA is projected to trade between $12.27 and $22.93, averaging $16.19 — a potential gain of +20% from today's $13.44. That is up +20% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Intellia Therapeutics, Inc.'s 2028 outlook centres on $18.70, within a $13.60 to $27.81 range. That is up +16% on the projected 2027 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2029, NTLA could reach as high as $28.06, with a base case around $18.17 and support toward $12.75 — roughly +35% from $13.44. Buyers look set to stay in control over this stretch.
Expect NTLA to range from $12.52 to $29.37 through 2030. The $18.42 average target implies a +37% move from current prices. That is up +1% on the projected 2029 average. Momentum favours further upside here.
The NTLA price prediction for 2031 points to an average of $25.61 (low $16.91, high $42.00) — a potential gain of +91% on today's $13.44. Buyers look set to stay in control over this stretch.
In 2032, NTLA is projected to trade between $19.12 and $50.05, averaging $29.77 — a potential gain of +122% from today's $13.44. That is up +16% on the projected 2031 average. Momentum favours further upside here.
Intellia Therapeutics, Inc.'s 2033 outlook centres on $32.35, within a $20.23 to $55.62 range. That is up +9% on the projected 2032 average. That marks a +141% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, NTLA could reach as high as $63.92, with a base case around $36.43 and support toward $22.21 — roughly +171% from $13.44. Momentum favours further upside here.
Expect NTLA to range from $20.82 to $62.57 through 2035. The $34.99 average target implies a +160% move from current prices. That is -4% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The NTLA price prediction for 2040 points to an average of $60.74 (low $32.25, high $117.53) — a potential gain of +352% on today's $13.44. Momentum favours further upside here.
In 2050, NTLA is projected to trade between $44.45 and $213.97, averaging $98.78 — a potential gain of +635% from today's $13.44. That is up +63% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NTLA today (≈ 74.404762 NTLA) could be worth
$7,349.87
+$6,349.87 (+635%) by 2050 · US Dollar
Based on the average projected NTLA price of $98.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NTLAwould be worth at today's price.
$1,000 invested in NTLA on May 27, 2025 (≈ 107.238608 NTLA) would be worth
$1,441.29
+$441.29 (+44.1%) today · 1.44× · US Dollar
Based on a NTLA entry price of $9.32 vs. today's $13.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.26 | $1,096.25 | +9.6% |
| 1 month ago | $13.04 | $1,030.67 | +3.1% |
| 3 months ago | $14.28 | $941.18 | -5.9% |
| 6 months ago | $8.99 | $1,494.99 | +49.5% |
| 1 year ago | $9.32 | $1,441.29 | +44.1% |
| All time (5.0y) ago | $73.73 | $182.29 | -81.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NTLA forecast.
Our base-case forecast reaches $27.00 around 2032.
Implied market cap at $27.00: $3.77B
The multi-year forecast paints a bullish trajectory beyond 2026, with notable milestones in key years. In 2030, the expected average price is $16.73, with a min of $11.35 and a max of $26.72, and an ROI of 32.8%. The long-run view shows continued upside, including a 2040 average of $52.48 and a max of $101.78, with an ROI of 316.5% and bullish sentiment.
By 2050, the average is projected at $83.37, with a max of $181.01 and an ROI of 561.6%, remaining in a bullish regime.
These forecasts imply substantial upside potential over the coming decades, even as near-term sentiment remains cautious and the 2026 projection is neutral. While the numbers indicate meaningful growth, they are estimates and do not guarantee future results. Investors should consider the inherent uncertainty and market volatility reflected in the long-run projections.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $16.73, with a range from $11.35 to $26.72 and a projected ROI of 32.8%. The sentiment for 2030 is bullish.
From 2027 onward, the forecast is bullish, with rising average prices and positive ROI figures (e.g., 2027 avg $15.12, ROI 20%; 2030 avg $16.73, ROI 32.8%). Note that these are estimates and not guarantees.
Yes. The 2050 forecast shows a max of $181.01 and an average of $83.37, with an ROI of 561.6% and bullish sentiment, indicating the potential to exceed $100 in the forecast horizon.
For 2026, the min is $9.21, the average is $12.60, and the max is $18.99, with neutral sentiment and an ROI of 0%.
The forecast points to substantial upside through 2040 and 2050, with 2040 average $52.48 (ROI 316.5%) and 2050 average $83.37 (ROI 561.6%). These figures reflect bullish outlooks but come with inherent uncertainty and market volatility as with any long-range projection.
Intellia Therapeutics, Inc. Community Discussion
0Share your Intellia Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.